AtriCure
Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 150,000 implanted to date.
Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 150,000 implanted to date.
Your career starts on Magnet.me
Create a profile and receive connection requests from interested companies.
Jobs
Interesting to know
This company page was generated automatically and therefore features only limited information. Find out more about AtriCure on their company website:
This company page was generated automatically and therefore features only limited information. Find out more about AtriCure on their company website:
People also viewed
Change language to: Dutch
This page is optimised for people from the Netherlands. View the version optimised for people from the UK.